Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Open Access
- 1 November 2001
- journal article
- clinical trial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 71 (5) , 589-595
- https://doi.org/10.1136/jnnp.71.5.589
Abstract
Objective: to analyse 24 parkinsonian patients successfully treated by bilateral STN stimulation for the presence of behavioural disorders. Method: patients were evaluated retrospectively for adjustment disorders (social adjustment scale, SAS), psychiatric disorders (comparison of the results of psychiatric interview and the mini international neuropsychiatric inventory) and personality changes (IOWA scale of personality changes). Results: parkinsonian motor disability was improved by 69.5% and the levodopa equivalent daily dosage was reduced by 60.5%. Social adjustment (SAS) was considered good or excellent in nine patients, moderately (n=14), or severely (n=1) impaired in 15 patients. Psychiatric disorders consisted of amplification or decompensation of previously existing disorders that had sometimes passed unnoticed, such as depressive episodes (n=4), generalised anxiety (n=18), and behavioural disorders with drug dependence (n=2). Appearance of mild to moderate emotional hyperreactivity was reported in 15 patients. Personality traits (IOWA scale) were improved in eight patients, unchanged in seven, and aggravated in eight Conclusion: Improvement in parkinsonian motor disability induced by STN stimulation is not necessarily accompanied by improvement in psychic function and quality of life. Attention is drawn to the possible appearance of personality disorders and decompensation of previous psychiatric disorders in parkinsonian patients who are suitable candidates for neurosurgery. We suggest that a careful psychological and psychiatric interview be performed before surgery, and emphasise the need for psychological follow up to ensure the best possible outcome.Keywords
This publication has 43 references indexed in Scilit:
- The Effects of Metrifonate on the Cognitive, Behavioral, and Functional Performance of Alzheimer's Disease PatientsThe Journal of Clinical Psychiatry, 1999
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Nicotinic System Involvement in Alzheimer??s and Parkinson??s DiseasesDrugs & Aging, 1997
- Use of Goal Attainment Scaling to Measure Treatment Effects in an Anti-Dementia Drug TrialNeuroepidemiology, 1996
- The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled TrialDementia and Geriatric Cognitive Disorders, 1996
- Improving the quality of reporting of randomized controlled trials. The CONSORT statementJAMA, 1996
- The Neuropsychiatric InventoryNeurology, 1994
- Predictors of the Placement of Cognitively Impaired Residents on Special Care UnitsThe Gerontologist, 1992
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982